Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma
{{output}}
Background: For unresectable or metastatic melanoma, first-line ipilimumab has demonstrated long-term survival benefits over a 7-year period. First-line treatment with BRAF inhibitors has demonstrated efficacy in clinical trials ... ...
